Bristol Myers Squibb last week entered a deal to acquire Turning Point Therapeutics, the clinical-state oncology company that’s currently developing a promising kinase inhibitor for non-small cell lung cancer (NSCLC) and advanced solid tumors. The drug, repotrectinib, targets ROS1 and NTRK gene mutations, and has seen solid trial results that could make it a major rival to Roche’s Rozlytrek. As a treatment for NSCLC, Rozlytrek currently holds covered or better status for 97% of all insured lives under the pharmacy benefit. 41.1% of insured lives have preferred access to Rozlytrek, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 6/6/22